{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:48:02Z","timestamp":1791110882312,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2022JH2\/101300050"],"award-info":[{"award-number":["2022JH2\/101300050"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M681021"],"award-info":[{"award-number":["2020M681021"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejso.2024.108474","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T16:47:29Z","timestamp":1717606049000},"page":"108474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery\/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"Ziming","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingguang","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4244-6855","authenticated-orcid":false,"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2024.108474_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.ejso.2024.108474_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2024.108474_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00384-014-2085-6","article-title":"Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands","volume":"30","author":"Elferink","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ejso.2024.108474_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review","volume":"100","author":"Baratti","year":"2016","journal-title":"Crit Rev Oncol-Hematol"},{"key":"10.1016\/j.ejso.2024.108474_bib5","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.soc.2018.02.011","article-title":"Peritoneal metastases from colorectal cancer: treatment Principles and perspectives","volume":"27","author":"Go\u00e9r\u00e9","year":"2018","journal-title":"Surg Oncol Clin"},{"key":"10.1016\/j.ejso.2024.108474_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11102840","article-title":"Current trends in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease from appendiceal and colorectal malignancies","volume":"11","author":"Harper","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejso.2024.108474_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejso.2024.108474_bib10","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/cncr.30424","article-title":"Clinical and genetic determinants of ovarian metastases from colorectal cancer","volume":"123","author":"Ganesh","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib11","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/1078-0432.CCR-10-1720","article-title":"KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer","volume":"17","author":"Tie","year":"2011","journal-title":"Clin Cancer Res : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.ejso.2024.108474_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/1471-2407-12-347","article-title":"Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer","volume":"12","author":"Kim","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrclinonc.2016.219","article-title":"First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm","volume":"14","author":"Cremolini","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib14","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1002\/cncr.28347","article-title":"Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases","volume":"119","author":"Karagkounis","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib15","first-page":"645","article-title":"Impact of somatic mutations on patterns of metastasis in colorectal cancer","volume":"6","author":"Lipsyc","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejso.2024.108474_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"European journal of epidemiology"},{"key":"10.1016\/j.ejso.2024.108474_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/0284186X.2018.1433322","article-title":"Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer","volume":"57","author":"Christensen","year":"2018","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"key":"10.1016\/j.ejso.2024.108474_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ijc.28955","article-title":"Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer","volume":"136","author":"Schirripa","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jss.2018.11.025","article-title":"Metastatic profile of colorectal cancer: interplay between primary tumor location and KRAS status","volume":"246","author":"Zihui Yong","year":"2020","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejso.2024.108474_bib21","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.6004\/jnccn.2016.0165","article-title":"Differential radiographic appearance of BRAF V600e-mutant metastatic colorectal cancer in patients matched by primary tumor location","volume":"14","author":"Atreya","year":"2016","journal-title":"J Natl Compr Cancer Netw : J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejso.2024.108474_bib22","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib23","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/cncr.28729","article-title":"BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer","volume":"120","author":"Yaeger","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1245\/s10434-019-07378-9","article-title":"RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification Proposal of the peritoneal Surface disease severity score","volume":"26","author":"Arjona-Sanchez","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib25","article-title":"RAS mutation status should not Be used to predict outcome from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases","author":"Bhullar","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib26","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s11605-021-05073-3","article-title":"Clinical and molecular features in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal Carcinosis from colorectal cancer","volume":"25","author":"Di Giorgio","year":"2021","journal-title":"J Gastrointest Surg : official journal of the Society for Surgery of the Alimentary Tract"},{"key":"10.1016\/j.ejso.2024.108474_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41416-021-01620-6","article-title":"Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients","volume":"126","author":"Larsen","year":"2022","journal-title":"British journal of cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","article-title":"Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin","volume":"268","author":"Schneider","year":"2018","journal-title":"Annals of surgery"},{"key":"10.1016\/j.ejso.2024.108474_bib29","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1245\/s10434-021-11045-3","article-title":"Microsatellite and RAS\/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"29","author":"Tonello","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib30","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1245\/s10434-023-13463-x","article-title":"Impact of primary tumor location and genomic alterations on survival following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for colorectal peritoneal metastases","volume":"30","author":"Hamed","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib31","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ejso.2022.06.014","article-title":"The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases","volume":"48","author":"Flood","year":"2022","journal-title":"Eur J Surg Oncol : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology"},{"key":"10.1016\/j.ejso.2024.108474_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jss.2019.02.050","article-title":"RAS mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer","volume":"240","author":"Morgan","year":"2019","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejso.2024.108474_bib33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/jso.26439","article-title":"Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS\/HIPEC","volume":"123","author":"Zhang","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib34","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1245\/s10434-020-09161-7","article-title":"Prognostic impact of primary side and RAS\/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases","volume":"28","author":"Baratti","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib35","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2024.108474_bib36","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s00423-021-02353-z","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes","volume":"406","author":"Rosa","year":"2021","journal-title":"Langenbeck's Arch Surg"},{"key":"10.1016\/j.ejso.2024.108474_bib37","first-page":"230","article-title":"[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]","volume":"24","author":"Yu","year":"2021","journal-title":"Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery"},{"key":"10.1016\/j.ejso.2024.108474_bib38","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1245\/s10434-017-5938-8","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for moderately and poorly differentiated appendiceal adenocarcinoma: survival outcomes and patient selection","volume":"24","author":"Grotz","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.108474_bib39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejso.2024.108474_bib40","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/codi.15003","article-title":"Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis","volume":"22","author":"Narasimhan","year":"2020","journal-title":"Colorectal Dis : the official journal of the Association of Coloproctology of Great Britain and Ireland"},{"key":"10.1016\/j.ejso.2024.108474_bib41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/djab190","article-title":"KRAS and BRAF mutations in stage II and III colon cancer: a systematic review and meta-analysis","volume":"114","author":"Formica","year":"2022","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.ejso.2024.108474_bib42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2024.108474_bib43","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/annonc\/mdx401","article-title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","volume":"28","author":"Sanz-Garcia","year":"2017","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324005262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T19:20:01Z","timestamp":1737314401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324005262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0748798324005262"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108474","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery\/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108474"}}